Stockscreener 앱 받기
30.57
0.46%
-0.14
전일 마감가:
$30.71
열려 있는:
$30.99
하루 거래량:
2.49M
Relative Volume:
1.26
시가총액:
$4.85B
수익:
$264.79M
순이익/손실:
$-14.36M
주가수익비율:
-277.91
EPS:
-0.11
순현금흐름:
$-28.11M
1주 성능:
+7.38%
1개월 성능:
-0.71%
6개월 성능:
-21.29%
1년 성능:
+4.91%
1일 변동 폭
$30.30
$31.25
1주일 범위
$26.89
$33.24
52주 변동 폭
$25.28
$46.48
TG테라퓨틱스사 Stock (TGTX) Company Profile
명칭
Tg Therapeutics Inc
전화
(212) 554-4484
주소
2 GANSEVOORT STREET, 9TH FLOOR, NEW YORK, NY
TGTX을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
TGTX
Tg Therapeutics Inc
|
30.57 | 4.88B | 264.79M | -14.36M | -28.11M | -0.11 |
|
VRTX
Vertex Pharmaceuticals Inc
|
441.36 | 111.36B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
733.04 | 77.98B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ARGX
Argen X Se Adr
|
800.01 | 50.33B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
359.27 | 47.46B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ONC
Beone Medicines Ltd Adr
|
338.19 | 37.43B | 4.98B | 69.59M | 525.67M | 0.5197 |
TG테라퓨틱스사 Stock (TGTX) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2025-10-06 | 재개 | H.C. Wainwright | Buy |
| 2025-07-10 | 재개 | Goldman | Neutral |
| 2024-10-29 | 개시 | TD Cowen | Buy |
| 2023-08-02 | 업그레이드 | Goldman | Sell → Neutral |
| 2023-06-26 | 재개 | Jefferies | Buy |
| 2022-05-20 | 개시 | BofA Securities | Underperform |
| 2022-02-23 | 재확인 | B. Riley Securities | Buy |
| 2021-11-15 | 다운그레이드 | Goldman | Neutral → Sell |
| 2021-04-20 | 개시 | Goldman | Neutral |
| 2021-04-19 | 재확인 | H.C. Wainwright | Buy |
| 2020-09-01 | 개시 | JP Morgan | Overweight |
| 2020-08-11 | 재확인 | H.C. Wainwright | Buy |
| 2020-06-05 | 개시 | Evercore ISI | Outperform |
| 2020-01-17 | 재확인 | H.C. Wainwright | Buy |
| 2019-11-27 | 재개 | B. Riley FBR | Buy |
| 2019-02-06 | 재개 | Jefferies | Buy |
| 2018-09-25 | 다운그레이드 | Raymond James | Strong Buy → Outperform |
| 2018-03-09 | 재확인 | B. Riley FBR, Inc. | Buy |
| 2017-12-01 | 재개 | B. Riley FBR, Inc. | Buy |
| 2017-11-14 | 재개 | H.C. Wainwright | Buy |
| 2017-04-25 | 개시 | Jefferies | Buy |
| 2017-03-06 | 재확인 | FBR & Co. | Outperform |
| 2016-10-06 | 재개 | Brean Capital | Buy |
| 2016-05-27 | 개시 | SunTrust | Buy |
| 2015-12-01 | 개시 | FBR Capital | Outperform |
| 2015-09-09 | 개시 | Raymond James | Strong Buy |
| 2015-08-12 | 재개 | H.C. Wainwright | Buy |
| 2015-06-19 | 재확인 | Brean Capital | Buy |
| 2014-12-11 | 재확인 | ROTH Capital | Buy |
| 2014-12-10 | 재확인 | ROTH Capital | Buy |
모두보기
TG테라퓨틱스사 주식(TGTX)의 최신 뉴스
Moving Averages: Should you avoid TG Therapeutics Inc stock right nowJuly 2025 Review & Fast Gain Stock Trading Tips - baoquankhu1.vn
TGTX rallies 8% after hours on revenue estimates based on strong Briumvi demand through 2026 - MSN
Q4 EPS Estimates for TG Therapeutics Raised by HC Wainwright - MarketBeat
Goldman Sachs Raises Price Target for TG Therapeutics (TGTX) to $39 | TGTX Stock News - GuruFocus
TG Therapeutics (NASDAQ:TGTX) Trading 7.5% HigherHere's Why - MarketBeat
TG Therapeutics: The 'Exit Velocity' You Can't Ignore (Rating Upgrade) - Seeking Alpha
HC Wainwright Forecasts TG Therapeutics FY2025 Earnings - MarketBeat
TG Therapeutics Announces Strong 2025 BRIUMVI Revenue Outlook - The Globe and Mail
TG Therapeutics Stock Rises 7% on Strong Q4 & 2025 Preliminary Results - The Globe and Mail
Goldman Sachs Raises TG Therapeutics Price Target to $39, Briumvi Now Available in 16 Countries - Intellectia AI
TG Therapeutics stock holds Overweight rating at Cantor Fitzgerald By Investing.com - Investing.com Canada
TG Therapeutics Target of Unusually Large Options Trading (NASDAQ:TGTX) - MarketBeat
TG Therapeutics Soars on Strong Revenue Guidance and BRIUMVI Mom - GuruFocus
TG Therapeutics (NASDAQ:TGTX) Shares Gap UpTime to Buy? - MarketBeat
TGTX Stock Surges Over 12% Amid Positive Market Movement - GuruFocus
TG Therapeutics, Clover Health Investments, Nutrien And Other Big Stocks Moving Higher On Wednesday - Benzinga
TG Therapeutics (TGTX) Receives a Sell from Bank of America Securities - The Globe and Mail
TG Therapeutics shares hit highest since November, last up 12.9% after prelim 2025 sales top estimate - marketscreener.com
Retail Traders Are Piling Into TG Therapeutics – What’s Driving The Chatter? - Asianet Newsable
Why TG Therapeutics Stock Is Moving Today - Benzinga
TG Therapeutics steigert Umsatzprognose für 2026 und übertrifft Umsatzprognose für 2025 - TradingView — Track All Markets
TG Therapeutics jumps on 2026 revenue outlook, prelim 2025 sales beat - TradingView — Track All Markets
Stock Market Today: S&P 500, Dow Jones, Nasdaq 100 Futures Tumble Ahead Of SC Ruling On Trump's Tariffs— Wells Fargo, BP, WeRide In Focus (UPDATED) - Benzinga
In the Wake of TG Therapeutics, Inc.'s (NASDAQ:TGTX) Latest US$225m Market Cap Drop, Institutional Owners May Be Forced to Take Severe Actions - 富途牛牛
Avoiding Lag: Real-Time Signals in (TGTX) Movement - Stock Traders Daily
SG Americas Securities LLC Boosts Stock Holdings in TG Therapeutics, Inc. $TGTX - MarketBeat
TGTX Rallies 7% After Hours On Revenue Estimates Based On Strong Briumvi Demand Through 2026 - Menafn
Bank of America, Citigroup And 3 Stocks To Watch Heading Into Wednesday - Benzinga
TG Therapeutics reports $616 million in preliminary 2025 revenue By Investing.com - Investing.com Nigeria
TG Therapeutics Stock Pre-Market (+7.0%) : Strong 2026 Revenue Guidance Issued - Trefis
TG Therapeutics Looks To ENHANCE Growth With Pivotal 2026 Trial Readout - RTTNews
TG Therapeutics Stock Pops As Briumvi Boom Reignites Bull Case: Goldman Sachs Sees Room For 32% Rally - Stocktwits
TG Therapeutics (TGTX) Projects Strong Revenue Growth for 2026 - GuruFocus
TGTX Sets 2026 Expense Forecast Amid New Developments - GuruFocus
TG Therapeutics Expects Briumvi Revenue of $825M to $850M in FY26 - Intellectia AI
TG Therapeutics jumps after preliminary 2025 sales exceed forecast - TradingView — Track All Markets
TG Therapeutics provides preliminary fourth quarter and full year 2025 results - marketscreener.com
Tg Therapeutics Provides Preliminary Fourth Quarter And Full Year 2025 Results - TradingView — Track All Markets
TG Therapeutics Stock Climbs After The Bell: Here's Why - Benzinga
TGTX Expects Strong Revenue Growth Driven by Briumvi Success - GuruFocus
TG Therapeutics Issues 2026 Revenue Outlook; Shares Rise After Hours - marketscreener.com
TG Therapeutics Provides Preliminary Fourth Quarter and Full Year 2025 Net Product Revenue and 2026 Revenue Guidance and Anticipated Development Milestones - The Manila Times
TG Therapeutics stock rises after strong 2025 revenue and positive 2026 outlook - Investing.com Canada
TG Therapeutics reports $616 million in preliminary 2025 revenue - Investing.com
MS drug maker TG Therapeutics targets $900M in 2026 sales, trial data ahead - Stock Titan
Notable Tuesday Option Activity: TGTX, SPOT, TECH - Nasdaq
Is TG Therapeutics' (TGTX) JPM Briumvi Update Quietly Reframing Its MS Commercial Narrative? - Sahm
Aug PostEarnings: Is TG Therapeutics Inc still a buy after recent gains2025 Buyback Activity & Safe Capital Investment Plans - baoquankhu1.vn
TG Therapeutics, Inc. (TGTX) Stock Analysis: A Biotech Gem With 56.56% Upside Potential - DirectorsTalk Interviews
TGTX Announces 2024 Preliminary Results, 2025 Goals, Shares Rise - MSN
TG Therapeutics stock slid nearly 7% Friday — what to watch next week for TGTX - TechStock²
TG테라퓨틱스사 (TGTX) 재무 분석
매출
순이익
현금흐름
주당 순 이익
4.73%
0.92%
자본화:
|
볼륨(24시간):